Glenmede Trust’s AnaptysBio ANAB Stock Holding History

Glenmede Trust’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$474K	Buy	7,016 +635	+10%	+$38.5K	﹤0.01%	1005
2026 Q1	$354K	Sell	6,381 -965	-13%	-$51.9K	﹤0.01%	1092
2025 Q4	$356K	Buy	+7,346	New	+$286K	﹤0.01%	1069
2025 Q1	$193K	Buy	+10,376	New	+$173K	﹤0.01%	1215
2020 Q4	–	Sell	-355	Closed	-$4K	–	1245
2020 Q3	$4K	Buy	355 +92	+35%	+$1.66K	﹤0.01%	2119
2020 Q2	$5K	Buy	+263	New	+$4.81K	﹤0.01%	2059

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Glenmede Trust's ANAB Position: Q2 2026 in Review

Glenmede Trust increased its AnaptysBio (ANAB) stake by 10% in Q2 2026, buying an estimated $38.5K and bringing the position to 7,016 shares worth $474K. The position accounts for ﹤0.01% of the portfolio, ranked #1005.

Glenmede Trust first reported a position in ANAB in Q2 2020 and has held it in 6 quarters since. 213 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

Glenmede Trust held 7,016 shares of AnaptysBio worth $474K as of Q2 2026.
Glenmede Trust bought 635 AnaptysBio shares in Q2 2026, an estimated $38.5K.
AnaptysBio made up ﹤0.01% of Glenmede Trust's portfolio in Q2 2026, its #1005 holding.
Glenmede Trust first reported a position in AnaptysBio in Q2 2020 and has held it in 6 quarters since.
213 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.